GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Shiller PE Ratio

Biogen (MEX:BIIB) Shiller PE Ratio : 11.70 (As of Jul. 24, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Shiller PE Ratio?

As of today (2024-07-24), Biogen's current share price is MXN4026.63. Biogen's E10 for the quarter that ended in Mar. 2024 was MXN344.25. Biogen's Shiller PE Ratio for today is 11.70.

The historical rank and industry rank for Biogen's Shiller PE Ratio or its related term are showing as below:

MEX:BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.23   Med: 28.3   Max: 110.75
Current: 10.76

During the past years, Biogen's highest Shiller PE Ratio was 110.75. The lowest was 9.23. And the median was 28.30.

MEX:BIIB's Shiller PE Ratio is ranked better than
86.04% of 530 companies
in the Drug Manufacturers industry
Industry Median: 24.105 vs MEX:BIIB: 10.76

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was MXN44.810. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is MXN344.25 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Shiller PE Ratio Historical Data

The historical data trend for Biogen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Shiller PE Ratio Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.24 15.16 13.53 13.69 12.51

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.49 13.58 12.33 12.51 10.23

Competitive Comparison of Biogen's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.



Biogen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=4026.63/344.25
=11.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=44.81/131.7762*131.7762
=44.810

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 39.038 100.560 51.157
201409 48.606 100.428 63.778
201412 55.165 99.070 73.377
201503 53.205 99.621 70.378
201506 61.662 100.684 80.704
201509 70.127 100.392 92.050
201512 64.825 99.792 85.602
201603 76.258 100.470 100.019
201606 88.584 101.688 114.795
201609 91.070 101.861 117.816
201612 61.645 101.863 79.748
201703 65.148 102.862 83.461
201706 73.569 103.349 93.805
201709 105.077 104.136 132.967
201712 -27.692 104.011 -35.084
201803 100.649 105.290 125.968
201806 82.135 106.317 101.804
201809 133.741 106.507 165.472
201812 92.874 105.998 115.461
201903 138.696 107.251 170.413
201906 150.790 108.070 183.868
201909 165.635 108.329 201.485
201912 152.389 108.420 185.217
202003 189.460 108.902 229.256
202006 221.357 108.767 268.183
202009 98.526 109.815 118.230
202012 46.149 109.897 55.337
202103 54.986 111.754 64.837
202106 59.519 114.631 68.421
202109 45.648 115.734 51.975
202112 51.285 117.630 57.453
202203 41.017 121.301 44.559
202206 145.654 125.017 153.529
202209 157.702 125.227 165.950
202212 73.890 125.222 77.758
202303 48.127 127.348 49.801
202306 69.776 128.729 71.428
202309 -8.187 129.860 -8.308
202312 29.026 129.419 29.555
202403 44.810 131.776 44.810

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (MEX:BIIB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biogen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024